Keap1在乳腺癌组织中的表达及临床意义
|
摘要
[目的]探讨Keap1在乳腺癌组织中的表达。[方法]选取2013年1月至2015年12月在武汉市武昌医院肿瘤科收治的原发乳腺肿瘤患者,其中病理诊断为乳腺癌80例(乳腺癌组)和乳腺良性肿瘤300例(乳腺良性肿瘤组),两组都进行Keap1的免疫组化分析与临床资料的调查分析。[结果]乳腺癌组的Keap1阳性表达率为70.0%,乳腺良性肿瘤组为7.8%,乳腺癌组的Keap1阳性表达率明显高于乳腺良性肿瘤组(P<0.05)。在80例乳腺癌患者中,Keap1的阳性表达与患者的病理类型、临床分期、淋巴结转移情况等有相关性(P<0.05)。多元回归Logistic分析结果显示,临床分期、淋巴结转移与病理类型是影响乳腺癌患者Keap1阳性表达的主要独立危险因素(P<0.05)。[结论]Keap1在乳腺癌组织中呈现高表达,且与患者的临床分期、淋巴结转移与病理类型明显相关,参与乳腺癌的发生与发展。
[Purpose] To investigate the Keap1 expression in breast cancer. [Methods] From January 2013 to December 2015 in our hospital oncology department,80 patients were diagnosed as breast cancer(breast cancer group) and 300 patients of benign breast tumor(benign breast tumor group)were selected,all patients were carried out clinical data investigation and Keap1 immunohistochemical analysis. [Results] The Keap1 positive expression rate in the breast cancer group was70.0%,while in the benign breast tumor group was 7.8%,the Keap1 positive expression rate in the breast cancer group was significantly higher than that in benign breast tumor group(P<0.05). In the80 patients with breast cancer,the Keap1 positive expression were significantly correlated to the type of disease,clinical stage,lymph node metastasis(P<0.05). Logistic regression analysis showed that clinical stage,lymph node metastasis and type of disease were the major independent risk factors affecting the expression of Keap1 in the breast cancer(P<0.05). [Conclusion] Keap1 is highly expressed in breast cancer tissue and the patient's type of disease,clinical stage,lymph node metastasis are significantly associated with the Keap1 positive expression,which participate in the occurrence and development of breast cancer.
[Purpose] To investigate the Keap1 expression in breast cancer. [Methods] From January 2013 to December 2015 in our hospital oncology department,80 patients were diagnosed as breast cancer(breast cancer group) and 300 patients of benign breast tumor(benign breast tumor group)were selected,all patients were carried out clinical data investigation and Keap1 immunohistochemical analysis. [Results] The Keap1 positive expression rate in the breast cancer group was70.0%,while in the benign breast tumor group was 7.8%,the Keap1 positive expression rate in the breast cancer group was significantly higher than that in benign breast tumor group(P<0.05). In the80 patients with breast cancer,the Keap1 positive expression were significantly correlated to the type of disease,clinical stage,lymph node metastasis(P<0.05). Logistic regression analysis showed that clinical stage,lymph node metastasis and type of disease were the major independent risk factors affecting the expression of Keap1 in the breast cancer(P<0.05). [Conclusion] Keap1 is highly expressed in breast cancer tissue and the patient's type of disease,clinical stage,lymph node metastasis are significantly associated with the Keap1 positive expression,which participate in the occurrence and development of breast cancer.
引文
[1]Tan L,Zhou X,Wang YZ,et al.Molecular classification of triple negative breast cancer and its applications[J].Cancer Research on Prevention and Treatment,2015,42(3):300-304.[谭莉,周茜,王艺蓁,等.三阴性乳腺癌的分子分型及应用[J].肿瘤防治研究,2015,42(3):300-304.]
[2]Zhu FB,Wei CY,Yang WP,et al.Expression of TGF-βRⅡin breast cancer and its relation to clinicopathological features[J].Zhejiang Medical Journal,2015,37(18):1518-1521.[朱非白,韦长元,杨伟萍,等.TGF-βRⅡ基因在乳腺癌中的表达及临床意义[J].浙江医学,2015,37(18):1518-1521.]
[3]Rauch GM,Hobbs BP,Kuerer HM,et al.Microcalcifications in 1657 patients with pure ductal carcinoma in situ of the breast:correlation with clinical,histopathologic,biologic features,and local recurrence[J].Ann Surg Oncol,2015,9(28):112-114.
[4]Chen L,Wang CF,Qiu L,et al.Expression and clinicopathological features of breast cancer HER-2 gene[J].Zhejiang Clinical Medical Journal,2015,17(3):423-425.[陈蕾,汪春福,邱立,等.乳腺癌HER-2基因的表达与临床病理特征的关系[J].浙江临床医学,2015,17(3):423-425.]
[5]Wijdeven RH,Pang B,van der Zanden SY,et al.Genomewide identification and characterization of novel factors conferring resistance to topoisomeraseⅡpoisons in cancer[J].Cancer Res,2015,75(19):4176-4187.
[6]Fu YX,Fan R,Zheng XY,et al.Expression and significance of erb B2,ER,PR,Ki67 in breast cancer[J].Chinese Journal of Practical Medicine,2015,42(21):80-81.[付勇先,范瑞,郑香玉,等.Cerb B2、ER、PR、Ki67在乳腺癌中的表达及意义[J].中国实用医刊,2015,42(21):80-81.]
[7]Tang M,Zhang QC,Zhang P,et al.Vaccine of Runx2-dendritic cells can induce specific lethal effect of triple negative breast cancer[J].Journal of Sun Yat-sen University(Medical Sciences),2015,36(3):377-384.[汤谧,张翘楚,张鹏,等.Runx2-树突状细胞基因疫苗诱导特异性细胞免疫杀伤三阴乳腺癌[J].中山大学学报(医学科学版),2015,36(3):377-384.]
[8]Winton LM,Nodora JN,Martinez ME,et al.Factors associated with surgical management in an underinsured,safety net population[J].Surgery,2015,3(15):655-658.
[9]Zhang JB,Lv XD,Song W,et al.Complementarity determining region 3 repertoire of clonal T cell receptorαchain in patients with micrometastasis from breast cancer[J].Cancer Research on Prevention and Treatment,2015,42(11):1109-1113.[张建波,吕晓东,宋魏,等.乳腺癌淋巴结微转移患者克隆性T细胞TCRα链CDR3谱型分析[J].肿瘤防治研究,2015,42(11):1109-1113.]
[10]Nestal de Moraes G,Castro CP,Salustiano EJ,et al.The pterocarpanquinone LQB-118 induces apoptosis in acute myeloid leukemia cells of distinct molecular subtypes and targets Fox O3a and Fox M1 transcription factors[J].Int J Oncol,2014,45(5):1949-1958.
[11]Yao YF,Tang JH,Ma R,et al.Expression of multidrug resistance-associated proteins in different molecular subtypes of breast cancer and their correlation with hormone receptors and HER-2[J].Chinese Journal of Oncology,2014,36(10):771-772.[姚宇锋,唐金海,马蓉,等.耐药基因蛋白在不同分子亚型乳腺癌中的表达及其与雌孕激素受体和人表皮生长因子受体2的关系[J].中华肿瘤杂志,2014,36(10):771-772.]
[12]Moshina N,Ursin G,Hoff SR,et al.Mammographic density and histopathologic characteristics of screen-detected tumors in the Norwegian Breast Cancer Screening Program[J].Acta Radiol Open,2015,4(9):2058-2060.
[13]Zhang Y,Song HZ,Wen H,et al.Osthole inhibits the proliferation of breast cancer MCF-7 cells via activating peroxisome proliferator-activated receptorγ[J].Cancer Research and Clinic,2015,27(6):375-380.[张岩,宋惠珠,温浩,等.蛇床子素通过过氧化物酶体增殖物活化受体γ抑制乳腺癌MCF-7细胞增殖的研究[J].肿瘤研究与临床,2015,27(6):375-380.]
[14]Xie YR,Wang XG,Pan Y,et al.Analysis of BRCA1 gene mutation in patients with familial breast cancer in Lishui[J].Journal of Chinese Oncology,2015,21(10):856-859.[谢艳茹,王晓光,潘颖,等.丽水市家族性乳腺癌患者BRCA1基因突变分析[J].肿瘤学杂志,2015,21(10):856-859.]
[15]Kim MS,Lee WS,Jin W.Trk B promotes breast cancer metastasis via suppression of Runx3 and Keap1 expression[J].Mol Cells,2015,12(10):67-69.
[16]Foygel K,Sekar TV,Paulmurugan R.Monitoring the antioxidant mediated chemosensitization and signaling in triple negative breast cancer therapy[J].PLo S One,2015,10(11):1913-1916.
[17]Lee HN,Jin HO,Park JA,et al.Heme oxygenase-1 determines the differential response of breast cancer and normal cells to piperlongumine[J].Mol Cells,2015,38(4):327-335.
[2]Zhu FB,Wei CY,Yang WP,et al.Expression of TGF-βRⅡin breast cancer and its relation to clinicopathological features[J].Zhejiang Medical Journal,2015,37(18):1518-1521.[朱非白,韦长元,杨伟萍,等.TGF-βRⅡ基因在乳腺癌中的表达及临床意义[J].浙江医学,2015,37(18):1518-1521.]
[3]Rauch GM,Hobbs BP,Kuerer HM,et al.Microcalcifications in 1657 patients with pure ductal carcinoma in situ of the breast:correlation with clinical,histopathologic,biologic features,and local recurrence[J].Ann Surg Oncol,2015,9(28):112-114.
[4]Chen L,Wang CF,Qiu L,et al.Expression and clinicopathological features of breast cancer HER-2 gene[J].Zhejiang Clinical Medical Journal,2015,17(3):423-425.[陈蕾,汪春福,邱立,等.乳腺癌HER-2基因的表达与临床病理特征的关系[J].浙江临床医学,2015,17(3):423-425.]
[5]Wijdeven RH,Pang B,van der Zanden SY,et al.Genomewide identification and characterization of novel factors conferring resistance to topoisomeraseⅡpoisons in cancer[J].Cancer Res,2015,75(19):4176-4187.
[6]Fu YX,Fan R,Zheng XY,et al.Expression and significance of erb B2,ER,PR,Ki67 in breast cancer[J].Chinese Journal of Practical Medicine,2015,42(21):80-81.[付勇先,范瑞,郑香玉,等.Cerb B2、ER、PR、Ki67在乳腺癌中的表达及意义[J].中国实用医刊,2015,42(21):80-81.]
[7]Tang M,Zhang QC,Zhang P,et al.Vaccine of Runx2-dendritic cells can induce specific lethal effect of triple negative breast cancer[J].Journal of Sun Yat-sen University(Medical Sciences),2015,36(3):377-384.[汤谧,张翘楚,张鹏,等.Runx2-树突状细胞基因疫苗诱导特异性细胞免疫杀伤三阴乳腺癌[J].中山大学学报(医学科学版),2015,36(3):377-384.]
[8]Winton LM,Nodora JN,Martinez ME,et al.Factors associated with surgical management in an underinsured,safety net population[J].Surgery,2015,3(15):655-658.
[9]Zhang JB,Lv XD,Song W,et al.Complementarity determining region 3 repertoire of clonal T cell receptorαchain in patients with micrometastasis from breast cancer[J].Cancer Research on Prevention and Treatment,2015,42(11):1109-1113.[张建波,吕晓东,宋魏,等.乳腺癌淋巴结微转移患者克隆性T细胞TCRα链CDR3谱型分析[J].肿瘤防治研究,2015,42(11):1109-1113.]
[10]Nestal de Moraes G,Castro CP,Salustiano EJ,et al.The pterocarpanquinone LQB-118 induces apoptosis in acute myeloid leukemia cells of distinct molecular subtypes and targets Fox O3a and Fox M1 transcription factors[J].Int J Oncol,2014,45(5):1949-1958.
[11]Yao YF,Tang JH,Ma R,et al.Expression of multidrug resistance-associated proteins in different molecular subtypes of breast cancer and their correlation with hormone receptors and HER-2[J].Chinese Journal of Oncology,2014,36(10):771-772.[姚宇锋,唐金海,马蓉,等.耐药基因蛋白在不同分子亚型乳腺癌中的表达及其与雌孕激素受体和人表皮生长因子受体2的关系[J].中华肿瘤杂志,2014,36(10):771-772.]
[12]Moshina N,Ursin G,Hoff SR,et al.Mammographic density and histopathologic characteristics of screen-detected tumors in the Norwegian Breast Cancer Screening Program[J].Acta Radiol Open,2015,4(9):2058-2060.
[13]Zhang Y,Song HZ,Wen H,et al.Osthole inhibits the proliferation of breast cancer MCF-7 cells via activating peroxisome proliferator-activated receptorγ[J].Cancer Research and Clinic,2015,27(6):375-380.[张岩,宋惠珠,温浩,等.蛇床子素通过过氧化物酶体增殖物活化受体γ抑制乳腺癌MCF-7细胞增殖的研究[J].肿瘤研究与临床,2015,27(6):375-380.]
[14]Xie YR,Wang XG,Pan Y,et al.Analysis of BRCA1 gene mutation in patients with familial breast cancer in Lishui[J].Journal of Chinese Oncology,2015,21(10):856-859.[谢艳茹,王晓光,潘颖,等.丽水市家族性乳腺癌患者BRCA1基因突变分析[J].肿瘤学杂志,2015,21(10):856-859.]
[15]Kim MS,Lee WS,Jin W.Trk B promotes breast cancer metastasis via suppression of Runx3 and Keap1 expression[J].Mol Cells,2015,12(10):67-69.
[16]Foygel K,Sekar TV,Paulmurugan R.Monitoring the antioxidant mediated chemosensitization and signaling in triple negative breast cancer therapy[J].PLo S One,2015,10(11):1913-1916.
[17]Lee HN,Jin HO,Park JA,et al.Heme oxygenase-1 determines the differential response of breast cancer and normal cells to piperlongumine[J].Mol Cells,2015,38(4):327-335.